Dizal (Jiangsu) Pharmaceutical (SHA:688192) will showcase the positive results of Golidocitinib and Birelentinib at an international convention, according to a Shanghai bourse filing on Wednesday.
Golidocitinib was tested as a treatment for peripheral T-cell lymphoma. The trial found that the drug can provide patients prolonged survival, deep remission, and comprehensive clinical benefits.
Meanwhile, Birelentinib was found to have a strong anti-tumor activity and good safety.
The Chinese pharmaceutical company will present the findings at the annual American Society of Hematology, which will be held between Dec. 6 and Dec. 9.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments